baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

UC BON.CAP.CERT. 12/24 SNW/ DE000HD5VD09 /

02/08/2024 21:46:51	Chg.+3.770	Bid21:59:52	Ask21:59:52	Underlying	Strike price	Expiration date	Option type
130.180EUR	+2.98%	130.340 Bid Size: 200	131.120 Ask Size: 200	SANOFI SA INHABER ...	- EUR	31/12/2024	Call

TeleTrader 25/07 Europe lower premarket as earnings pour in

TeleTrader 25/07 Sanofi net sales up 7.8% to €10.7B in Q2

GlobeNewswire 28/06 Verve Therapeutics Announces Appointment of Nia Tatsis, Ph.D., and Jodie Morrison to its Board of Di...

TeleTrader 27/06 Europe opens mixed before consumer confidence data

GlobeNewswire 27/06 Vigil Neuroscience Announces $40 Million Strategic Investment from Sanofi

GlobeNewswire 26/06 Dupixent® (dupilumab) Positive Phase 3 Data in Children 1 to 11 Years of Age with Eosinophilic Esoph...

GlobeNewswire 26/06 Press Release: Dupixent positive phase 3 data in children one to 11 years of age with eosinophilic e...

GlobeNewswire 21/06 Press Release: Audrey Duval Derveloy appointed Global Head of Corporate Affairs, member of Sanofi’s ...

GlobeNewswire 21/06 Press Release: ISTH: Sanofi advances leadership in hemophilia with new data for ALTUVIIIO and fitusi...

GlobeNewswire 20/06 Press Release: Sanofi and Biovac spearhead polio vaccine manufacturing capabilities in Africa

GlobeNewswire 18/06 Belharra Therapeutics Announces Strategic Collaboration with Sanofi to Advance Discovery of Novel Sm...

GlobeNewswire 11/06 Kevzara® (sarilumab) Approved by FDA for the Treatment of Active Polyarticular Juvenile Idiopathic A...

GlobeNewswire 03/06 Press Release: ASCO: Sarclisa is first anti-CD38 to significantly improve progression-free survival ...

GlobeNewswire 31/05 Press Release: Sanofi launches 2024 global Employee Stock Purchase Plan

GlobeNewswire 31/05 Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Patients with COPD

GlobeNewswire 31/05 Press Release: Dupixent recommended for EU approval by the CHMP to treat patients with COPD

GlobeNewswire 31/05 Update on FDA Priority Review of Dupixent® (dupilumab) for the Treatment of COPD Patients with Type ...

GlobeNewswire 31/05 Press Release: Update on FDA priority review of Dupixent for the treatment of COPD patients with typ...

GlobeNewswire 30/05 Press Release: Sanofi completes acquisition of Inhibrx, Inc.

GlobeNewswire 27/05 Press Release: Sarclisa accepted for FDA priority review for the treatment of transplant-ineligible ...

GlobeNewswire 23/05 CRISPR Therapeutics Strengthens Executive Leadership Team with Key Appointments

GlobeNewswire 21/05 Press Release: Sanofi, Formation Bio and OpenAI announce first-in-class AI collaboration

GlobeNewswire 20/05 Dupixent® (dupilumab) Late-Breaking Data from NOTUS Confirmatory Phase 3 COPD Trial Presented at ATS...

GlobeNewswire 20/05 Press Release: Dupixent® late-breaking data from NOTUS confirmatory phase 3 COPD study presented at ...

GlobeNewswire 20/05 Shah Capital Withdraws Proxy Campaign Against Re-Election of Directors at Novavax’s 2024 Annual Meet...

UC BON.CAP.CERT. 12/24 SNW/ DE000HD5VD09 /

If you wish to receive reply to your feedback, please provide your email address.